Merck has announced that its Phase 3 KEYNOTE-119 trial assessing Keytruda (pembrolizumab) monotherapy compared to chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine) in 2L and 3L metastatic triple-negative breast cancer (TNBC) patients did not meet the primary endpoint of OS.
In accordance with the study protocol, other endpoints (PFS, ORR, disease control rate, and duration of response) were not formally tested since OS was not met.
Merck plans to present these results at an upcoming medical conference.
The LIBERTY 1 study met its primary efficacy endpoint with 73.4% of women receiving once daily oral relugolix combination therapy achieving the responder criteria compared with 18.9% of women receiving placebo (p < 0.0001). Response was defined as a menstrual blood loss volume of less than 80 mL and a 50 percent or greater reduction from baseline in menstrual blood loss volume during the last 35 days of the 24-week treatment period.
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2019-05-20 17:24:162019-05-20 18:04:29Myovant Reports Phase 3 Data of Relugolix in Uterine Fibroids
Sutro has provided updates on preclinical BCMA ADC and BCMA/CD3 bispecific antibody programs that are part of a Celgene immuno-oncology collaboration formed in 2014.
According to an updated label, FDA has granted accelerated approval to use of Keytruda (pembrolizumab; PD-1) in combination with Inlyta (axitinib; TKI) in 1L renal cell carcinoma (RCC).
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2019-04-25 17:32:272019-05-20 18:05:00Keytruda/Inlyta combo granted accelerated approval by FDA for 1L advanced RCC
Novartis has contributed $75 million towards a Series C financing for CAR-T company Poseida, which totaled $142 million from current and new investors.
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2019-04-22 17:36:082019-05-20 18:06:14Novartis remains in BCMA CAR-T space through Poseida investment after discontinuing in-house program
